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Abstract: Recent technology enables the use of cell-free fetal DNA in maternal plasma and serum for noninvasive prenatal genetic
diagnosis. This study was designed to evaluate factors most likely to influence the success of a simple, cost efficient, reliable and
replicable conventional PCR technique in the clinical routine of prenatal genetic diagnosis of selected cases. The results strongly
suggest that DNA extraction and PCR cycle optimization are 2 major success-limiting steps and the maternal plasma is a better choice
over serum for DNA extraction for such prenatal genetic diagnosis. In addition, the use of a ready-to-use PCR mixture containing
heat-activated Taq polymerase significantly reduced the risk of nonspecific amplification and of primer dimerization formed at low
temperatures during PCR setup and the initial PCR cycle eliminating false positive results and insufficient PCR amplification,
respectively. Thus the ease, rapidity and effectiveness shown by the presented system requiring only optimization of routine PCR
procedure and no additional sophisticated equipment could theoretically reduce the cost and number of invasive procedures required
for prenatal diagnosis of X-linked recessive genetic disorders and of fetal RhD status.
Key Words: Noninvasive prenatal diagnosis, maternal plasma, maternal serum, fetal gender determination, conventional multiplex
PCR

Introduction
Recent technology enables the use of both intact fetal
cells (1-3) and cell-free fetal DNA (4-13) in maternal
plasma and/or serum for noninvasive prenatal genetic
diagnosis. However, circulating fetal cells in maternal
blood are extremely rare and the techniques used for the
isolation, enrichment and processing of these cells are
very time consuming and intensive. Thus, the use of this
approach has been limited in clinical routine. On the other
hand, cell-free fetal DNA in the maternal plasma and/or
serum offers a promising noninvasive alternative for fetal
gender, which can be used for clinical pre-testing for Xlinked genetic diseases, and RhD status determination
(6,14-16).

The concentration of fetal DNA in maternal plasma
was found to be much higher than that present in the
cellular fraction (4). Lo et al. (5) showed that during early
pregnancy fetal DNA concentrations were, on average,
3.4% of the total DNA in the maternal plasma and 0.13%
in serum. Even though the highest concentration of fetal
DNA seems to be present in maternal plasma, some
researchers have had better specificity and sensitivity
results with maternal serum samples (10,17,18),
whereas others suggested using the maternal plasma
(4,8,13). Comparable results with both maternal plasma
and serum have been reported when highly sensitive
techniques, such as real-time quantitative polymerase
chain reaction (PCR), are used for the determination of
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fetal gender or RhD status (19-21). However, expensive
equipment renders their application difficult in a routine
setting. Thus, especially for diagnostic facilities with
limited financial resources, a simple, cost efficient,
reliable and replicable conventional PCR technique may be
an alternative solution to utilize this analysis in a routine
clinical setting.
This study was designed to evaluate the factors most
likely to influence the success of such a conventional PCR
technique in the clinical routine of prenatal genetic
diagnosis. The success rates of 2 different DNA extraction
techniques, which were used in previous studies on both
maternal plasma and serum samples in a conventional
multiplex PCR setting, were compared. In addition, the
importance of PCR cycle number optimization, use of a
ready-to-use PCR mixture, and heat activated Taq
polymerase for the accuracy of such prenatal genetic
diagnosis has also been demonstrated in this study.

Materials and Methods
Patients and Sample Collection
Peripheral blood and amniotic fluid samples were
obtained from 33 pregnant women undergoing
amniocentesis at Pamukkale University Hospital,
Department of Obstetrics and Gynecology. The study was
approved by the Pamukkale University Medical Ethics
Committee. All of the pregnant women participating in
this study were selected at random and gave informed
written consent before blood sampling. All underwent
blood sampling before amniocentesis. At the time of
blood collection, the gestational ages ranged from 16
weeks to 20 weeks (mean ± SEM, 17.67 ± 0.22).
Peripheral blood samples obtained from 5 healthy
men were used to determine the PCR specificity and
sensitivity, whereas peripheral blood samples obtained
from 5 non-pregnant women served as negative controls.
In each case, 2-3 ml of peripheral blood was collected into
an EDTA-containing tube for plasma separation, and 7-8
ml of peripheral blood was collected into a plain tube
containing no anticoagulant for serum separation. The
blood samples were centrifuged at 3000g for 10 min,
and the plasma and serum were carefully removed from
their respective tubes and transferred into plain
polypropylene tubes. The plasma and serum samples then
underwent a second centrifugation at 3000g for 10 min,
and these recentrifuged plasma and serum samples were
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transferred into fresh polypropylene tubes. The samples
were stored at -20 °C until further processing.
Amniotic fluid samples (1-2 ml per patient) collected
from the same group of pregnant women undergoing
amniocentesis were stored at +4 °C until further
processing and were used for fetal sex determination. An
amniotic fluid sample from each patient also underwent
cytogenetic analysis for complete karyotyping.
DNA Extraction from Plasma and Serum Samples
DNA from plasma and serum samples was extracted
using either the heat-based direct method (22) or the
QIAamp DNA Blood Mini Kit method (Qiagen, Hilden,
Germany) according to the “blood and body fluid
protocol” (10,13), with minor modifications in each case.
Briefly, in the case of the heat-based direct extraction
method 200 µl of plasma or serum in a 0.5 µl sterile
Eppendorf tube was heated at 99 °C for 5 min. The
heated sample was then centrifuged at maximum speed in
a microcentrifuge, after which the clear supernatant was
collected and 10 µl used for PCR. In the case of the
QIAamp DNA Blood Mini Kit method, on the other hand,
DNA was extracted from 400 µl of plasma or serum and
was eluted into a final volume of 50 µl, and 5 µl was used
as template for PCR analysis.
Each DNA solution extracted from the healthy men
was serially diluted from 1:10 to 1:1000 to estimate the
sensitivity of the PCR used. In addition, the 1:100 diluted
samples from these control men were used for PCR cycle
optimization study.
DNA Extraction from amniocytes
To extract DNA from amniocytes 500 µl of amniotic
fluid was transferred to a 0.5 ml sterile Eppendorf tube.
Cells were pelleted at 10,000x g for 2 min and the
supernatant discarded. Pellets were resuspended in 30 µl
of sterile water and heated at 99 °C for 5 min. Samples
were cooled and centrifuged at maximum speed in a
microcentrifuge, after which the clear supernatant was
collected and 10 µl used for PCR.
PCR conditions
The Y-chromosome-specific sequence DYS14 (198
bp) and an autosomal locus, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (97 bp), were co-amplified in a
multiplex PCR setting for the detection of fetal DNA in
maternal plasma/serum and to assess the presence of
DNA, respectively. We used the primers Y1.7 (5’-
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CATCCAGAGCGTCCCTGGCTT-3’) and Y1.8 (5’CTTTCCACAGCCACATTTGTC-3’) for DYS14 (23) and
forward (5’-CCCCACACACATGCACTTACC-3’) and reverse
(5’-CCTAGTCCCAGGGCTTTGATT-3’) for GAPDH (24).
All PCR amplifications were performed in a total volume
of 50 µl containing extracted DNA, 20 pmol of each
primer (Y1.7, Y1.8, GAPDH forward, and GAPDH
reverse), and 25 µl of HotStarTaq Master Mix
(containing 2.5 units of HotStarTaq DNA polymerase, 1 x
PCR buffer with 1.5 mM MgCl2, and 200 µM of each
dNTP (Qiagen, Hilden, Germany)). To test the importance
of using a ready-to-use PCR mixture, plasma DNA
samples from selected pregnant women were further
PCR amplified with same components individually
purchased (all from Qiagen, Hilden, Germany) and added
to each reaction at the same concentrations as above and
the results were compared. In addition, to test the
importance of using a heat-activated Taq polymerase
enzyme, plasma DNA samples from selected pregnant
women were further PCR amplified with Taq PCR Master
Mix (Qiagen, Hilden, Germany) containing the same
components at the same concentrations as above, except
for the HotStarTaq, which was replaced with a regular
Taq polymerase.
The thermal cycling was as follows: initial activation of
HotStarTaq DNA polymerase at 95 °C for 15 min,
followed by 40 cycles of denaturation at 94 °C for 1 min,
annealing at 57 °C for 1 min, and extension at 72 °C for
1 min, with final extension at 72 °C for 10 min. The PCR
cycle number was optimized using the same conditions
with the modification of the cycle number, i.e. 30, 40,
and 50 cycles. The PCR amplification products were
separated by 2% agarose gel electrophoresis and
visualized by exposure to ultraviolet light after ethidium
bromide staining.
Samples were only tested once and the success rates
of different DNA extraction techniques, i.e. the heatbased direct method or the QIAamp DNA Blood Mini Kit
method, as well as the sources of the DNA extracted, i.e.
plasma or serum, were compared to each other on the
basis of the accuracy of single PCR results.
Anticontamination measures
Great care was taken to prevent PCR contamination
(25). Aerosol-resistant pipette tips were used for all
liquids. Separate areas were used for the extraction of
DNA, the preparation of amplification reactions, the

carrying out of amplification reactions, and the detection
of the PCR products. A female author performed all DNA
extraction and PCR amplification procedures.
Statistical analysis
Data on the success rates of different DNA extraction
methods or different materials, from which DNA was
extracted, were analyzed by testing for the difference
between 2 population proportions.

Results
Using representative healthy control male and nonpregnant control female DNA samples it was
demonstrated that in our multiplex PCR setup the DYS14
sequence represents the male gender, whereas the
GAPDH sequence was used as an internal control for the
presence of extracted genomic DNA (Figure 1A).
DNA samples from all 5 healthy males, either
extracted via the heat-based direct method or the QIAamp
DNA Blood Mini Kit method from either plasma or serum
were PCR positive for both DYS14 and GAPDH sequences
(data not shown). However, DNA samples from all 5 nonpregnant women for either extraction method from
either material were PCR negative for the DYS14
sequence and PCR positive for the GAPDH sequence (data
not shown). Thus, the gender specificity of either DNA
extraction method from either material was 100%.
The sensitivities of these DNA extraction methods for
the DYS14 sequence, on the other hand, did differ from
each other for both materials (Figure 1B). The sensitivity
(S) of even the best DNA sample extracted via the heatbased direct method from either material was within the
dilution limits of 1:1000 < S < 1:100 (Figure 1B lower
panel). However, that of an average DNA sample
extracted via the QIAamp DNA Blood Mini Kit method for
either material was always S < 1:1000 (Figure 1B upper
panel).
To optimize the PCR cycle number used in this study
a series of reactions with 1:100 dilutions of healthy
control male DNA extracted from either material using
either method was performed using different cycle
numbers, i.e. 30, 40, and 50 cycles, whereas all other
reaction conditions were kept constant. The results
showed that 40 cycles gave the optimum results with
100% sensitivity and specificity (data not shown).
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Figure.

A) Multiplex PCR setup for DYS14 and GAPDH sequence. B) Analysis of the sensitivity of PCR used for gender
determination. C) Analysis of the effect of PCR cycle number on the accuracy of prenatal genetic diagnosis results.
D) Analysis of the effect of different PCR setup techniques on the accuracy of prenatal genetic diagnosis results.
E) Analysis of the use of heat activated Taq polymerase versus regular Taq polymerase on the accuracy of
prenatal genetic diagnosis results.

Cytogenetic analysis of cultured amniocytes revealed
that 17 of the pregnant women were carrying a male
fetus and the remaining 16 pregnant women were
carrying a female fetus (Table). One of the female fetuses
was cytogenetically detected with trisomy-13 (Table,
patient 16). Optimized PCR results obtained with DNA
extracted from amniocytes and from maternal plasma
using the QIAamp DNA Blood Mini Kit method were in
complete agreement with the cytogenetic analyses in
terms of gender determination (Table).
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All other optimized PCR attempts failed to obtain
100% accuracy for the diagnosis of fetal gender (Table).
DNA extracted from maternal serum using the QIAamp
DNA Blood Mini Kit method gave 31 accurate and 2 false
negative (Table, patient 5 and 21) results. DNA extracted
from maternal serum using the heat-based direct method
gave 29 accurate results, 2 inconclusive results due to
smear-like appearance (Table, patient 1 and 4), and 2
false negative (Table, patient 13 and 24) results. Finally,
DNA extracted from maternal plasma using the heatbased direct method gave 29 accurate results, 1
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Table. Fetal gender determination in pregnancies at risk of genetic disorders.
DYS14 / GAPDH amplification
Patient No.

Week of
gestation

Karyotype

Risk
Plasma
Amniocytes (A)

Kit (B)

Serum
Heat (C)

Kit (D)

Heat (E)

1

20

46, XX

-/+

-/+

-/+

-/+

Smear

S

2

16

46, XY

+/+

+/+

+/+

+/+

+/+

MA

3

18

46, XX

-/+

-/+

-/+

-/+

-/+

S+MA

4

16

46, XX

-/+

-/+

-/+

-/+

Smear

MA

5

19

46, XY

+/+

+/+

+/+

6

17

46, XY

+/+

+/+

7

18

46, XY

+/+

+/+

8

16

46, XY

+/+

9

17

46, XY

+/+

10

16

46, XX

11

19

46, XX

12

18

13
14

- / +*

+/+

MA

+/+

+/+

MA

+/+

+/+

+/+

S

+/+

+/+

+/+

+/+

MA

+/+

+/+

+/+

+/+

NT

-/+

-/+

-/+

-/+

-/+

S

-/+

-/+

-/+

-/+

-/+

S

46, XY

+/+

+/+

+/+

+/+

+/+

S

20

46, XY

+/+

+/+

+/+

+/+

- / +*

DS

17

46, XX

-/+

-/+

-/+

-/+

-/+

MA

15

18

46, XX

-/+

-/+

- / -**

-/+

-/+

S

16

16

47, XX+13

-/+

-/+

-/+

-/+

-/+

S

17

18

46, XX

-/+

-/+

-/+

-/+

-/+

S

18

17

46, XX

-/+

-/+

-/+

-/+

-/+

S

19

17

46, XX

-/+

-/+

-/+

-/+

-/+

MA

20

19

46, XX

-/+

-/+

-/+

-/+

-/+

S

21

17

46, XY

+/+

+/+

+/+

- / +*

+/+

S

22

19

46, XY

+/+

+/+

+/+

+/+

+/+

S

23

18

46, XX

-/+

-/+

Smear

-/+

-/+

MA

24

19

46, XY

+/+

+/+

+/+

+/+

- / +*

MA

25

17

46, XY

+/+

+/+

+/+

+/+

+/+

S

26

18

46, XX

-/+

-/+

-/+

-/+

-/+

MA

27

16

46, XY

+/+

+/+

+/+

+/+

+/+

S

28

19

46, XY

+/+

+/+

+/+

+/+

+/+

S

29

17

46, XX

-/+

-/+

-/+

-/+

-/+

MA

30

20

46, XY

+/+

+/+

- / +*

+/+

+/+

S

31

16

46, XX

-/+

-/+

-/+

-/+

-/+

MA

32

17

46, XY

+/+

+/+

+/+

+/+

+/+

S

33

18

46, XY

+/+

+/+

+/+

+/+

+/+

S

Mean (±SEM):17.68 (±0.25)

Accuracy:

100%

100%

88%

94%

88%

Range:

δ
Accuracy:Kit (B+D) = 97% versus Heat (C+E) = 88% (P < 0.03)

16-20

- / +*

S, Screening; MA, maternal age; NT, nuccal translucency; DS, history of child with Down Syndrome; *, false negative; **, no amplification; SEM,
standard error of the mean.
δ
Statistically different by the test for difference between 2 population proportions (P < 0.03).
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inconclusive result due to smear-like appearance (Table,
patient 23), 2 false negative (Table, patients 6 and 30)
results, and 1 inconclusive result due to the absence of
amplifiable genomic DNA (Table, patient 15).
To demonstrate the importance of PCR cycle number
optimization for such prenatal genetic diagnosis studies,
maternal plasma-DNA extracted via the QIAamp DNA
Blood Mini Kit method from 4 male- and 4 female-fetus
carrying pregnant women, whose PCR results with
optimized 40 cycles were in 100% accordance with the
results from cytogenetic testing, were further PCR
amplified using either 30 cycles or 50 cycles. Results
from 4 male-fetus carrying pregnant women with 30
cycles showed no false negative results. However, the
DYS14 products were quite faint and difficult to detect (a
representative sample is shown in Figure 1C, lane 2). On
the other hand, results from 2 out of 4 female-fetus
carrying pregnant women at 50 cycles showed false
positive and/or non specific results (Figure 1C, lanes 3
and 4).
The use of a ready-to-use PCR mixture containing
heat-activated Taq polymerase significantly reduced the
risk of nonspecific and/or false positive amplifications and
eliminated insufficient PCR amplification due to primer
dimerization formed at low temperatures during PCR
setup or the initial PCR cycle (Figure 1D and E,
respectively). Again, maternal plasma DNA extracted via
the QIAamp DNA Blood Mini Kit method from 4 maleand 4 female-fetus carrying pregnant women was tested.
When PCR components were added individually to each
reaction 2 out of 8 samples showed nonspecific products
(Figure 1D, lanes 1 and 2) and 1 out of 4 female-fetus
carrying pregnant women samples showed a false
positive result for DYS14 product (Figure 1D, lane 4). On
the other hand, when a regular Taq polymerase was used
for PCR amplification all reactions showed significant
primer dimerization (representative samples are shown in
Figure 1e, lanes 1-5), 2 out of 8 samples showed
nonspecific products (Figure 1E, lanes 3 and 5) and 1 out
of 4 male-fetus carrying pregnant women samples
showed a false negative result for DYS14 product (Figure
1E, lane 1). In addition, the remaining 3 accurate DYS14
products in the regular Taq group were quite faint and
difficult to detect when compared to those in the
HotStarTaq group (Figure 1E, lanes 3-5).
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Discussion
This study was designed to compare the success rates
of 2 different DNA extraction techniques, the heat-based
direct method and the QIAamp DNA Blood Mini Kit
method, used extensively in previous studies on both
maternal plasma and serum samples in a conventional
multiplex PCR setting to determine the best material and
the protocol to be used for prenatal gender diagnosis.
The crucial role of PCR optimization has also been
demonstrated.
Our results indicated that the diagnostic accuracy of
serum (94% with QIAamp DNA Blood Mini Kit extraction,
and 88% with heat-based direct extraction) and plasma
(100% with QIAamp DNA Blood Mini Kit extraction, and
88% with heat-based direct extraction) samples did not
differ statistically from each other when compared within
the same DNA extraction group (P > 0.05). On the other
hand, the cumulative (plasma and serum samples
together) accuracy of QIAamp DNA Blood Mini Kit
extraction (97%) was significantly higher than that of
heat-based direct extraction (88%; P < 0.03) suggesting
that DNA extraction may indeed be one of the major
success-limiting steps in such prenatal genetic diagnosis.
The PCR results of serial dilutions of DNA extracted with
either QIAamp DNA Blood Mini Kit or the heat-based
direct method support this hypothesis. The sensitivity of
even the best DNA sample extracted via the heat-based
direct method from either plasma or serum was within
the dilution limits of 1:1000 < S < 1:100 (Figure 1B,
lower panel). However, that of an average DNA sample
extracted via the QIAamp DNA Blood Mini Kit method for
either material was always S < 1:1000 (Figure 1B, upper
panel). Thus, the QIAamp DNA Blood reagent set or
equivalent is one of the best methods for extracting DNA
from plasma or serum. Heat-based extraction, on the
other hand, is cost efficient and very fast, although it
seemed inadequate for some of the studied samples
(Table).
In terms of the material utilized, this study indicated
no significant difference between serum and plasma,
although plasma samples scored the best, i.e. 100%,
accuracy. The slightly better accuracy of plasma samples
compared to that of serum samples may well be due to
the concentration difference of cell-free fetal DNA
contained in maternal plasma versus serum. Lo et al. (5)
showed that during early pregnancy fetal DNA
concentrations were, on average, 3.4% of the total DNA
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in maternal plasma and 0.13% in serum. In this regard,
our results are also in agreement with those of previous
studies (4,8,13), which showed either no significant
difference between plasma and serum sample accuracy
(plasma being the more successful) (4), or plasma as a
better choice for DNA extraction (8,13).
This study also highlights the significance of
amplification cycle number optimization for such prenatal
genetic diagnostic studies. As demonstrated here (Figure
1C), over-amplification of sample DNA increases the risk
of false positive results due to nonspecific amplification.
In addition, ready-to-use PCR mixtures containing all the
necessary components except for the template DNA and
primers significantly reduce the pipetting steps involved
in the PCR setup, thus reducing the risk of sample
contamination and nonspecific amplification (Figure 1D).
Another significant contribution to the technique is the
use of heat activated Taq polymerase, which is inactive at
ambient temperatures preventing extension of
nonspecifically annealed primers and primer-dimers
formed at low temperatures during PCR setup and the
initial PCR cycle as demonstrated in Figure 1E.

and number of invasive procedures required for prenatal
diagnosis of X-linked recessive genetic disorders since
they might be necessary for male fetuses only,
significantly avoiding invasive procedures for female
fetuses. This technique may also be used for the safe and
rapid evaluation of fetal RhD status. It is also important
to remember that 2 previous studies (10,13) have
demonstrated the detection of cell-free fetal DNA from
either maternal plasma (13) or serum (10) as early as 7th10th gestational weeks, further strengthening the
advantage of such prenatal diagnosis in terms of timing
during pregnancy as an alternative to invasive techniques
in selected cases.
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